Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin
Robert I
RI
Division of Endocrinology and Metabolism, Food and Drug Administration, Silver Spring, Maryland, USA. robert.misbin@fda.hhs.gov
D002986:Clinical Trials as Topic / Q000592:standards; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone